Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription Articles published in Eur J Radiol Retrieve available abstracts of 43 articles: HTML format

Single Articles

June 2020
1. WEI CG, Chen T, Zhang YY, Pan P, et al
   Erratum to "Biparameteric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels" [Eur. J. Radiol. 127 (2020) 108977].
   Eur J Radiol. 2020 Jun 21:109129. doi: 10.1016/j.ejrad.2020.109129.
   PubMed    
   
   
   May 2020
2. MAHJOUB S, Baur ADJ, Lenk J, Lee CH, et al
   Optimizing size thresholds for detection of clinically significant prostate cancer on MRI: Peripheral zone cancers are smaller and more predictable than transition zone tumors.
   Eur J Radiol. 2020;129:109071.
   PubMed     Abstract available
   
   
   April 2020
3. ZHANG W, Mao N, Wang Y, Xie H, et al
   A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients.
   Eur J Radiol. 2020;128:109020.
   PubMed     Abstract available
   
   
   
4. WEI CG, Chen T, Zhang YY, Pan P, et al
   Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
   Eur J Radiol. 2020;127:108977.
   PubMed     Abstract available
   
   
   February 2020
5. CHEN Z, Xue Y, Zhang Z, Li W, et al
   The performance of intravoxel-incoherent motion diffusion-weighted imaging derived hypoxia for the risk stratification of prostate cancer in peripheral zone.
   Eur J Radiol. 2020;125:108865.
   PubMed     Abstract available
   
   
   October 2019
6. BECKER AS, Chaitanya K, Schawkat K, Muehlematter UJ, et al
   Variability of manual segmentation of the prostate in axial T2-weighted MRI: A multi-reader study.
   Eur J Radiol. 2019;121:108716.
   PubMed     Abstract available
   
   
   
7. TAMADA T, Kido A, Takeuchi M, Yamamoto A, et al
   Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
   Eur J Radiol. 2019;121:108704.
   PubMed     Abstract available
   
   
   September 2019
8. SAUER M, Tennstedt P, Berliner C, Well L, et al
   Predictors of short and long term urinary incontinence after radical prostatectomy in prostate MRI: Significance and reliability of standardized measurements.
   Eur J Radiol. 2019;120:108668.
   PubMed     Abstract available
   
   
   
9. CUOCOLO R, Stanzione A, Ponsiglione A, Verde F, et al
   Prostate MRI technical parameters standardization: A systematic review on adherence to PI-RADSv2 acquisition protocol.
   Eur J Radiol. 2019;120:108662.
   PubMed     Abstract available
   
   
   
10. SCHNEIDER AF, Stocker D, Hotker AM, Eberli D, et al
    Comparison of PSA-density of the transition zone and whole gland for risk stratification of men with suspected prostate cancer: A retrospective MRI-cohort study.
    Eur J Radiol. 2019;120:108660.
    PubMed     Abstract available
    
    
    
11. DING K, Yao Y, Gao Y, Lu X, et al
    Diagnostic evaluation of diffusion kurtosis imaging for prostate cancer: Detection in a biopsy population.
    Eur J Radiol. 2019;118:138-146.
    PubMed     Abstract available
    
    
    
12. CRISTEL G, Esposito A, Damascelli A, Briganti A, et al
    Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
    Eur J Radiol. 2019;118:51-57.
    PubMed     Abstract available
    
    
    July 2019
13. DANIEL M, Polanec SH, Wengert G, Clauser P, et al
    Intra- and inter-observer variability in dependence of T1-time correction for common dynamic contrast enhanced MRI parameters in prostate cancer patients.
    Eur J Radiol. 2019;116:27-33.
    PubMed     Abstract available
    
    
    
14. SCHAUDINN A, Gawlitza J, Mucha S, Linder N, et al
    Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Eur J Radiol. 2019;116:180-185.
    PubMed     Abstract available
    
    
    
15. CUOCOLO R, Stanzione A, Ponsiglione A, Romeo V, et al
    Clinically significant prostate cancer detection on MRI: A radiomic shape features study.
    Eur J Radiol. 2019;116:144-149.
    PubMed     Abstract available
    
    
    June 2019
16. MIN X, Li M, Dong D, Feng Z, et al
    Multi-parametric MRI-based radiomics signature for discriminating between clinically significant and insignificant prostate cancer: Cross-validation of a machine learning method.
    Eur J Radiol. 2019;115:16-21.
    PubMed     Abstract available
    
    
    May 2019
17. HERMIE I, Van Besien J, De Visschere P, Lumen N, et al
    Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Eur J Radiol. 2019;114:92-98.
    PubMed     Abstract available
    
    
    
18. XU M, Fang M, Zou J, Yang S, et al
    Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions.
    Eur J Radiol. 2019;114:38-44.
    PubMed     Abstract available
    
    
    
19. LI W, Xin C, Zhang L, Dong A, et al
    Comparison of diagnostic performance between two prostate imaging reporting and data system versions: A systematic review.
    Eur J Radiol. 2019;114:111-119.
    PubMed     Abstract available
    
    
    April 2019
20. LI M, Huang Z, Yu H, Wang Y, et al
    Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: A meta-analysis.
    Eur J Radiol. 2019;113:225-231.
    PubMed     Abstract available
    
    
    
21. LINDGREN BELAL S, Sadik M, Kaboteh R, Enqvist O, et al
    Deep learning for segmentation of 49 selected bones in CT scans: First step in automated PET/CT-based 3D quantification of skeletal metastases.
    Eur J Radiol. 2019;113:89-95.
    PubMed     Abstract available
    
    
    
22. ULLRICH T, Arsov C, Quentin M, Laqua N, et al
    Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Eur J Radiol. 2019;113:1-6.
    PubMed     Abstract available
    
    
    March 2019
23. ONAY A, Vural M, Armutlu A, Ozel Yildiz S, et al
    Evaluation of the most optimal multiparametric magnetic resonance imaging sequence for determining pathological length of capsular contact.
    Eur J Radiol. 2019;112:192-199.
    PubMed     Abstract available
    
    
    January 2019
24. GHOLIZADEH N, Greer PB, Simpson J, Denham J, et al
    Characterization of prostate cancer using diffusion tensor imaging: A new perspective.
    Eur J Radiol. 2019;110:112-120.
    PubMed     Abstract available
    
    
    
25. AMINSHARIFI A, Gupta RT, Tsivian E, Sekar S, et al
    Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy.
    Eur J Radiol. 2019;110:7-13.
    PubMed     Abstract available
    
    
    
26. BARRETT T, Lawrence EM, Priest AN, Warren AY, et al
    Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis.
    Eur J Radiol. 2019;110:22-29.
    PubMed     Abstract available
    
    
    October 2018
27. MA S, Xu K, Xie H, Wang H, et al
    Diagnostic efficacy of b value (2000 s/mm(2)) diffusion-weighted imaging for prostate cancer: Comparison of a reduced field of view sequence and a conventional technique.
    Eur J Radiol. 2018;107:125-133.
    PubMed     Abstract available
    
    
    
28. SAUER M, Klene C, Kaul M, Quitzke A, et al
    Preoperative evaluation of pelvine lymph node metastasis in high risk prostate cancer with intravoxel incoherent motion (IVIM) MRI.
    Eur J Radiol. 2018;107:1-6.
    PubMed     Abstract available
    
    
    July 2018
29. CUOCOLO R, Stanzione A, Rusconi G, Petretta M, et al
    PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naive patient population.
    Eur J Radiol. 2018;104:64-70.
    PubMed     Abstract available
    
    
    May 2018
30. AKIN-AKINTAYO O, Tade F, Mittal P, Moreno C, et al
    Prospective evaluation of fluciclovine ((18)F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients.
    Eur J Radiol. 2018;102:1-8.
    PubMed     Abstract available
    
    
    
31. CZARNIECKI M, Caglic I, Grist JT, Gill AB, et al
    Role of PROPELLER-DWI of the prostate in reducing distortion and artefact from total hip replacement metalwork.
    Eur J Radiol. 2018;102:213-219.
    PubMed     Abstract available
    
    
    April 2018
32. REISCHAUER C, Patzwahl R, Koh DM, Froehlich JM, et al
    Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases-A pilot study.
    Eur J Radiol. 2018;101:184-190.
    PubMed     Abstract available
    
    
    
33. DI CAMPLI E, Delli Pizzi A, Seccia B, Cianci R, et al
    Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.
    Eur J Radiol. 2018;101:17-23.
    PubMed     Abstract available
    
    
    February 2018
34. BENNDORF M, Waibel L, Kronig M, Jilg CA, et al
    Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement.
    Eur J Radiol. 2018;99:62-67.
    PubMed     Abstract available
    
    
    January 2018
35. LI J, Weng Z, Xu H, Zhang Z, et al
    Support Vector Machines (SVM) classification of prostate cancer Gleason score in central gland using multiparametric magnetic resonance images: A cross-validated study.
    Eur J Radiol. 2018;98:61-67.
    PubMed     Abstract available
    
    
    
36. SAUER M, Weinrich JM, Fraune C, Salomon G, et al
    Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy.
    Eur J Radiol. 2018;98:187-192.
    PubMed     Abstract available
    
    
    
37. GRIVAS N, Hinnen K, de Jong J, Heemsbergen W, et al
    Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology.
    Eur J Radiol. 2018;98:107-112.
    PubMed     Abstract available
    
    
    October 2017
38. HANSEN NL, Koo BC, Warren AY, Kastner C, et al
    Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection.
    Eur J Radiol. 2017;95:307-313.
    PubMed     Abstract available
    
    
    September 2017
39. BECKER AS, Cornelius A, Reiner CS, Stocker D, et al
    Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.
    Eur J Radiol. 2017;94:58-63.
    PubMed     Abstract available
    
    
    August 2017
40. BENNDORF M, Hahn F, Kronig M, Jilg CA, et al
    Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Eur J Radiol. 2017;93:9-15.
    PubMed     Abstract available
    
    
    July 2017
41. KIM SH, Choi MS, Kim MJ, Kim YH, et al
    Role of semi-quantitative dynamic contrast-enhanced MR imaging in characterization and grading of prostate cancer.
    Eur J Radiol. 2017 Jul 6. pii: S0720-048X(17)30276.
    PubMed     Abstract available
    
    
    June 2017
42. PARK SY, Shin SJ, Jung DC, Cho NH, et al
    PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer.
    Eur J Radiol. 2017;91:22-28.
    PubMed     Abstract available
    
    
    May 2017
43. ULLRICH T, Quentin M, Oelers C, Dietzel F, et al
    Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality.
    Eur J Radiol. 2017;90:192-197.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: